Peraso Inc. witnessed a substantial decline in its stock price during Tuesday’s trading session, following the release of fourth-quarter earnings that missed analysts’ expectations.

The company reported a quarterly loss of $8.52 per share, significantly wider than the anticipated loss of $3.76 per share. Additionally, quarterly sales stood at $1.83 million, slightly surpassing the projected $1.70 million.

As a result, Peraso shares plummeted by 23.3% to $1.32 on Tuesday.

Let’s explore the performance of other stocks that grabbed attention during the mid-day session.

Climbers

• Ontrak, Inc. OTRK shares surged by a remarkable 197.8% to $0.5660 before the company’s presentation at the 36th Annual Roth Conference.
• Fusion Pharmaceuticals Inc. FUSN experienced a substantial 97.3% gain, reaching $20.99 after unveiling its acquisition deal with AstraZeneca. Furthermore, Leerink Partners downgraded the stock from Outperform to Market Perform but raised its price target from $17 to $21.
• SCWorx Corp. WORX saw a surge of 74% to $3.22.
• Spire Global, Inc. SPIR climbed 50.7% to $18.50 after announcing a collaboration with NVIDIA to enhance AI-driven weather forecasting.
• Enveric Biosciences, Inc ENVB witnessed a 43.6% increase to $1.5801 following the announcement of term sheet agreements with an undisclosed biotechnology firm, aimed at developing cannabinoid-COX-2 conjugate compounds for joint disease treatment.
• Zoomcar Holdings, Inc. ZCAR rose by 33.1% to $1.57 after revealing a partnership with EaseMyTrip to integrate its cars into the travel platform.
• Hoth Therapeutics, Inc. HOTH experienced a substantial 32% surge to $1.51 following the announcement of promising pre-clinical research on HT-ALZ for Alzheimer’s disease.
• Enliven Therapeutics, Inc. ELVN gained 27.2% to $16.09. The company disclosed a $90 million private placement financing and provided updates on its pipeline.
• National CineMedia, Inc. NCMI rose by 25.5% to $5.30 after reporting positive fourth-quarter results and introducing a new $100 million share repurchase program. The company anticipates first-quarter total revenue within the range of $34.5 million to $35.5 million.
• Alignment Healthcare, Inc. ALHC observed a 17.7% increase to $5.50.
• Crinetics Pharmaceuticals, Inc. CRNX rose by 15% to $43.63 following successful results from the Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly.
• Li-Cycle Holdings Corp. LICY experienced a 14% climb to $1.2540 after revealing progress in enhancing its liquidity position and conducting an internal technical review of the Rochester Hub.
• Verb Technology Company, Inc. VERB gained 12.5% to $0.4055 post an 18% drop on Monday. The company announced the launch of its Market.live Facebook and Instagram social shopping technology integration on Friday.
• Monopar Therapeutics Inc. MNPR witnessed a 12% increase to $0.75.
• Nordstrom, Inc. JWN gained 11.9% to $19.10 following reports of the company’s founding family collaborating with Morgan Stanley and Centerview Partners to potentially take the company private.
• Alpine Immune Sciences, Inc. ALPN observed a 10.3% increase to $39.13 after releasing its fourth-quarter earnings.
• Nocturne Acquisition Corporation MBTC rose by 10% to $11.00.
• DocGo Inc. DCGO gained 10% to $4.0550, with the company announcing common stock repurchases and the adoption of a 10b5-1 trading plan for its share repurchase program.
• Augmedix, Inc. AUGX observed a 9.3% increase to $3.6399 post encouraging fourth-quarter results.
• International Paper Company IP climbed 7% to $37.38. The company appointed Andrew Silvernail as Chief Executive Officer after a thorough evaluation process.

Decliners

• Greenwave Technology Solutions, Inc. GWAV witnessed a steep 56.2% decline to $0.1634 after restructuring its senior secured debt.
• Seelos Therapeutics, Inc. SEEL fell by 46.6% to $0.4901 post the announcement that its ALS study with SLS-005 did not meet statistical significance in the primary and secondary endpoints in the Full Analysis Set.
• Comtech Telecommunications Corp. CMTL dipped 26.7% to $3.37 following underwhelming quarterly results.